Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 42(3); September 2010
Prev issue Next issue
Review Article
RNA Regulation in Neurologic Disease and Cancer
Robert B. Darnell
Cancer Res Treat. 2010;42(3):125-129.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.125
AbstractAbstract PDFPubReaderePub

The paraneoplastic neurologic diseases (PNDs) are brain degenerations that develop in the setting of clinically inapparent cancers. PNDs arise when common cancers express brain proteins, triggering an anti-tumor immune response and tumor immunity. Research on these brain-cancer proteins has revealed a new world of neuron-specific RNA binding proteins whose functions may be aberrantly used by tumor cells. Efforts to gain insight into their function has led to the development of new methods and strategies to understand RNA protein regulation in living tissues.

Citations

Citations to this article as recorded by  
  • LARP6 suppresses colorectal cancer progression through ZNF267/SGMS2-mediated imbalance of sphingomyelin synthesis
    Xiaoli Long, Xunhua Liu, Ting Deng, Jianxiong Chen, Jiawen Lan, Sijing Zhang, Miao Zhou, Dan Guo, Jun Zhou
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • Effect and mechanism of circRNAs in tumor angiogenesis and clinical application
    Luyang Zhao, Yuying Guo, Yaxin Guo, Xiang Ji, Dandan Fan, Chen Chen, Weitang Yuan, Zhenqiang Sun, Zhenyu Ji
    International Journal of Cancer.2022; 150(8): 1223.     CrossRef
  • Widespread autogenous mRNA–protein interactions detected by CLIP-seq
    Thomas H Kapral, Fiona Farnhammer, Weihao Zhao, Zhi J Lu, Bojan Zagrovic
    Nucleic Acids Research.2022; 50(17): 9984.     CrossRef
  • Computational tools to study RNA-protein complexes
    Sneha Bheemireddy, Sankaran Sandhya, Narayanaswamy Srinivasan, Ramanathan Sowdhamini
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • RNA Regulators in Leukemia and Lymphoma
    Camila Prieto, Michael G. Kharas
    Cold Spring Harbor Perspectives in Medicine.2020; 10(5): a034967.     CrossRef
  • Diverse roles of RNA‐binding proteins in cancer traits and their implications in gastrointestinal cancers
    Kiyoshi Masuda, Yuki Kuwano
    WIREs RNA.2019;[Epub]     CrossRef
  • MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change
    Qianru He, Lini Zhao, Xiaobai Liu, Jian Zheng, Yunhui Liu, Libo Liu, Jun Ma, Heng Cai, Zhen Li, Yixue Xue
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • KHDRBS3 regulates the permeability of blood–tumor barrier via cDENND4C/miR-577 axis
    Peiqi Wu, Yang Gao, Shuyuan Shen, Yixue Xue, Xiaobai Liu, Xuelei Ruan, Lianqi Shao, Yunhui Liu, Ping Wang
    Cell Death & Disease.2019;[Epub]     CrossRef
  • IDH1 fine-tunes cap-dependent translation initiation
    Lichao Liu, J Yuyang Lu, Fajin Li, Xudong Xing, Tong Li, Xuerui Yang, Xiaohua Shen, Zefeng Wang
    Journal of Molecular Cell Biology.2019; 11(10): 816.     CrossRef
  • Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer
    Samantha Moore, Aino I Järvelin, Ilan Davis, Gareth L Bond, Alfredo Castello
    Current Opinion in Genetics & Development.2018; 48: 112.     CrossRef
  • Graphene Oxide-Facilitated Comprehensive Analysis of Cellular Nucleic Acid Binding Proteins for Lung Cancer
    Zhi Shang, Liqiang Qian, Sha Liu, Xiaomin Niu, Zhi Qiao, Yan Sun, Yan Zhang, Liu-Yin Fan, Xin Guan, Cheng-Xi Cao, Hua Xiao
    ACS Applied Materials & Interfaces.2018; 10(21): 17756.     CrossRef
  • NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer
    Andrew T. Ludlow, Mandy Sze Wong, Jerome D. Robin, Kimberly Batten, Laura Yuan, Tsung-Po Lai, Nicole Dahlson, Lu Zhang, Ilgen Mender, Enzo Tedone, Mohammed E. Sayed, Woodring E. Wright, Jerry W. Shay
    Nature Communications.2018;[Epub]     CrossRef
  • Identification and Analysis of Key Residues in Protein–RNA Complexes
    A. Kulandaisamy, Ambuj Srivastava, Pradeep Kumar, R. Nagarajan, S. Binny Priya, M. Michael Gromiha
    IEEE/ACM Transactions on Computational Biology and Bioinformatics.2018; 15(5): 1436.     CrossRef
  • RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment
    Suntaek Hong
    Journal of Cancer Prevention.2017; 22(4): 203.     CrossRef
  • The expanding universe of ribonucleoproteins: of novel RNA-binding proteins and unconventional interactions
    Benedikt M. Beckmann, Alfredo Castello, Jan Medenbach
    Pflügers Archiv - European Journal of Physiology.2016; 468(6): 1029.     CrossRef
  • NOVA2-mediated RNA regulation is required for axonal pathfinding during development
    Yuhki Saito, Soledad Miranda-Rottmann, Matteo Ruggiu, Christopher Y Park, John J Fak, Ru Zhong, Jeremy S Duncan, Brian A Fabella, Harald J Junge, Zhe Chen, Roberto Araya, Bernd Fritzsch, A J Hudspeth, Robert B Darnell
    eLife.2016;[Epub]     CrossRef
  • Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases
    Magdalena Jazurek, Adam Ciesiolka, Julia Starega-Roslan, Katarzyna Bilinska, Wlodzimierz J. Krzyzosiak
    Nucleic Acids Research.2016; : gkw803.     CrossRef
  • UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis
    Laurence Wurth, Panagiotis Papasaikas, David Olmeda, Nadine Bley, Guadalupe T. Calvo, Santiago Guerrero, Daniela Cerezo-Wallis, Javier Martinez-Useros, María García-Fernández, Stefan Hüttelmaier, Maria S. Soengas, Fátima Gebauer
    Cancer Cell.2016; 30(5): 694.     CrossRef
  • Tumor-promoting function and prognostic significance of the RNA-binding protein T-cell intracellular antigen-1 in esophageal squamous cell carcinoma
    Junichi Hamada, Katsutoshi Shoda, Kiyoshi Masuda, Yuji Fujita, Takuya Naruto, Tomohiro Kohmoto, Yuko Miyakami, Miki Watanabe, Yasusei Kudo, Hitoshi Fujiwara, Daisuke Ichikawa, Eigo Otsuji, Issei Imoto
    Oncotarget.2016; 7(13): 17111.     CrossRef
  • RNA-binding proteins, multifaceted translational regulators in cancer
    Laurence Wurth, Fátima Gebauer
    Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.2015; 1849(7): 881.     CrossRef
  • RNA-binding proteins in neurological diseases
    HuaLin Zhou, Marie Mangelsdorf, JiangHong Liu, Li Zhu, Jane Y Wu
    Science China Life Sciences.2014; 57(4): 432.     CrossRef
  • A versatile assay for RNA-binding proteins in living cells
    Claudia Strein, Anne-Marie Alleaume, Ulrich Rothbauer, Matthias W. Hentze, Alfredo Castello
    RNA.2014; 20(5): 721.     CrossRef
  • RNA-binding proteins in Mendelian disease
    Alfredo Castello, Bernd Fischer, Matthias W. Hentze, Thomas Preiss
    Trends in Genetics.2013; 29(5): 318.     CrossRef
  • Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins
    Alfredo Castello, Bernd Fischer, Katrin Eichelbaum, Rastislav Horos, Benedikt M. Beckmann, Claudia Strein, Norman E. Davey, David T. Humphreys, Thomas Preiss, Lars M. Steinmetz, Jeroen Krijgsveld, Matthias W. Hentze
    Cell.2012; 149(6): 1393.     CrossRef
  • Alternative splicing interference by xenobiotics
    Emanuela Zaharieva, J. Kevin Chipman, Matthias Soller
    Toxicology.2012; 296(1-3): 1.     CrossRef
  • Neural antigen‐specific autoimmune disorders
    Raffaele Iorio, Vanda A. Lennon
    Immunological Reviews.2012; 248(1): 104.     CrossRef
  • Paraneoplastic encephalomyelopathies: pathology and mechanisms
    Andrew McKeon, Sean J. Pittock
    Acta Neuropathologica.2011; 122(4): 381.     CrossRef
  • 13,609 View
  • 106 Download
  • 27 Crossref
Close layer
Original Articles
Quality of Life of Long-Term Survivors after a Distal Subtotal Gastrectomy
Seung Soo Lee, Ho Young Chung, Wansik Yu
Cancer Res Treat. 2010;42(3):130-134.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.130
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to investigate the impact of a distal subtotal gastrectomy on the quality of life (QoL).

Materials and Methods

The QoL data of 126 patients were obtained on their 5th annual follow-up visit after a curative distal subtotal gastrectomy for gastric cancer (Group A). The QoL data of 130 age- and gender-adjusted healthy population were obtained from the individuals who visited the health screening center for a medical check-up (Group B). There were 42 women and 84 men in the study group and their mean age was 56.0±11.1 years. QoL was assessed using the Korean versions of the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30) and QLQ-STO22.

Results

The EORTC QLQ-C30 global health status and QoL scores of Group A and Group B were 63.9±22.7 and 61.3±22.1, respectively (p=0.361). Group A revealed a better score for emotional functioning (84.1±16.1 and 75.2±21.4, respectively; p<0.001), cognitive functioning (82.0±16.4 and 75.0±21.4, respectively; p=0.004) and fatigue (27.7±20.8 and 33.8±23.2, respectively; p=0.028). However, Group A revealed a worse score for nausea and vomiting (14.8±20.0 and 10.2±16.0, respectively; p=0.042), financial difficulties (14.8±22.9 and 7.1±16.1, respectively; p=0.002), reflux (16.7±17.7 and 10.1±17.0, respectively; p=0.003), eating restrictions (13.6±15.2 and 6.6±10.2, respectively; p<0.001) and body image (23.3±25.4 and 16.2±24.6, respectively; p=0.023).

Conclusion

The QoL of long-term survivors after a distal subtotal gastrectomy is still influenced by the surgery itself even though they are considered to be free of disease.

Citations

Citations to this article as recorded by  
  • The impact of the 30-day postoperative complications on the quality of life following gastrectomy for gastric carcinoma: A prospective study
    Aelee Jang, Oh Jeong
    European Journal of Surgical Oncology.2023; 49(5): 983.     CrossRef
  • Surgery Matters: Progress in Surgical Management of Gastric Cancer
    Katharina Beyer
    Current Treatment Options in Oncology.2023; 24(2): 108.     CrossRef
  • Impact on quality of life with affirmative feedback on weight loss after gastrectomy
    Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
    Scientific Reports.2023;[Epub]     CrossRef
  • Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: A propensity score-matched cohort study
    Jianhong Yu, Zaozao Wang, Hong Yang, Chenghai Zhang, Jiadi Xing, Ming Cui, Hui Liu, Yu Wu, Xiangqian Su
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Quality of Life of Young Gastric Cancer Survivors: An Interpretation in the Context of Our Society
    Seung Soo Lee
    Medicina.2023; 60(1): 9.     CrossRef
  • Health-related quality of life after curative resection for gastric adenocarcinoma
    Jan Grosek, Hana Zavrtanik, Aleš Tomažič
    World Journal of Gastroenterology.2021; 27(16): 1816.     CrossRef
  • Gastrointestinal Disease–Specific Survivorship Care: A New Personalized Model Integrating Onco-Wellness
    Tai Hutchinson, Sarah Hoffe, Sabrina Saeed, Sonya A. Pflanzer, Jason B. Fleming, Smitha Pabbathi
    Cancer Control.2021;[Epub]     CrossRef
  • Partial Gastrectomy is Associated with Improved Overall Survival in Signet-Ring Cell Gastric Cancer
    Maitham A. Moslim, Elizabeth Handorf, Sanjay S. Reddy, Stephanie H. Greco, Jeffrey M. Farma
    Journal of Surgical Research.2021; 266: 27.     CrossRef
  • Health-related quality of life after gastric cancer treatment in Brazil: Narrative review and reflections
    Rodrigo Nascimento Pinheiro, Samantha Mucci, Renato Morato Zanatto, Olavo Magalhães Picanço Junior, Alexandre Ferreira Oliveira, Gaspar de Jesus Lopes Filho
    World Journal of Clinical Cases.2021; 9(17): 4123.     CrossRef
  • Comparison of unpalatable meal contents between patients who underwent total and distal gastrectomies
    Megumi Kitagawa, Yuko Uesugi, Naomi Kawata, Yasuhiro Shimamura
    Clinical Nutrition ESPEN.2020; 37: 134.     CrossRef
  • Quality of life, coping, and psychological and physical symptoms after surgery for non-metastatic digestive tract cancer
    Caterina Calderón, Paula Jiménez-Fonseca, Raquel Hernández, María del Mar Muñoz, Margarida Mut, Montserrat Mangas-Izquierdo, M Ángeles Vicente, Avinash Ramchandani, Alberto Carmona-Bayonas
    Surgical Oncology.2019; 31: 26.     CrossRef
  • Factors influencing the quality of life of patients with advanced cancer
    Sun-A Park, Seung Hyun Chung, Youngjin Lee
    Applied Nursing Research.2017; 33: 108.     CrossRef
  • Chronological Changes in Quality of Life after Distal Gastrectomy for Gastric Cancer
    Ki Bum Park, Seung Soo Lee, Oh Kyoung Kwon, Ho Young Chung, Wansik Yu
    Journal of Gastric Cancer.2017; 17(2): 110.     CrossRef
  • Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center
    Vivian E. Strong, Sepideh Gholami, Manish A. Shah, Laura H. Tang, Yelena Y. Janjigian, Mark Schattner, Luke V. Selby, Sam S. Yoon, Erin Salo-Mullen, Zsofia K. Stadler, David Kelsen, Murray F. Brennan, Daniel G. Coit
    Annals of Surgery.2017; 266(6): 1006.     CrossRef
  • Assessment of patient-reported outcome measures in the surgical treatment of patients with gastric cancer
    Jennifer Straatman, Nicole van der Wielen, Pieter J. Joosten, Caroline B. Terwee, Miguel A. Cuesta, Elise P. Jansma, Donald L. van der Peet
    Surgical Endoscopy.2016; 30(5): 1920.     CrossRef
  • Chronological Changes of Quality of Life in Long-Term Survivors after Gastrectomy for Gastric Cancer
    Wansik Yu, Ki Bum Park, Ho Young Chung, Oh Kyoung Kwon, Seung Soo Lee
    Cancer Research and Treatment.2016; 48(3): 1030.     CrossRef
  • Type D Personality in Gastric Cancer Survivors: Association With Poor Quality of Life, Overall Survival, and Mental Health
    Jia-kui Zhang, Li-li Fang, De-wei Zhang, Qiu Jin, Xiao-mei Wu, Ji-chao Liu, Chun-dong Zhang, Dong-qiu Dai
    Journal of Pain and Symptom Management.2016; 52(1): 81.     CrossRef
  • Quality of life: A critical outcome for all surgical treatments of gastric cancer
    Michael D McCall
    World Journal of Gastroenterology.2016; 22(3): 1101.     CrossRef
  • Body image in cancer survivors: a systematic review of case-control studies
    Vicky Lehmann, Mariët Hagedoorn, Marrit A. Tuinman
    Journal of Cancer Survivorship.2015; 9(2): 339.     CrossRef
  • Long-term Shifting Patterns in Quality of Life After Distal Subtotal Gastrectomy
    Seung Soo Lee, Ho Young Chung, Ohkyoung Kwon, Wansik Yu
    Annals of Surgery.2015; 261(6): 1131.     CrossRef
  • Cancer survivorship
    Gianmauro Numico, Vito Longo, Giulia Courthod, Nicola Silvestris
    Current Opinion in Oncology.2015; 27(4): 351.     CrossRef
  • Quality of life after subtotal gastrectomy for gastric cancer: Does restoration method matter? – A retrospective cohort study
    Edgaras Smolskas, Raimundas Lunevicius, Narimantas Evaldas Samalavicius
    Annals of Medicine and Surgery.2015; 4(4): 371.     CrossRef
  • Development and Evaluation of Korean Version of Quality of Sexual Function (QSF-K) in Healthy Korean Women
    Yumi Lee, Myong Cheol Lim, Yedong Son, Jungnam Joo, KiByung Park, Jung-Sup Kim, Dong Ock Lee, Sang-Yoon Park
    Journal of Korean Medical Science.2014; 29(6): 758.     CrossRef
  • Postoperative Changes in Body Weight, Anxiety, Depression, and Quality of Life after Radical Gastrectomy among Patients with Gastric Cancer
    Jin Ha Kim, Ja Yun Choi
    Asian Oncology Nursing.2014; 14(3): 139.     CrossRef
  • Quality of Life After Gastrectomy for Adenocarcinoma
    Paul J. Karanicolas, Dennis Graham, Mithat Gönen, Vivian E. Strong, Murray F. Brennan, Daniel G. Coit
    Annals of Surgery.2013; 257(6): 1039.     CrossRef
  • Long term quality of life in conservatively treated gastric lymphoma patients versus gastrectomized patients and gastritis patients
    Jesse Lachter, Ron Shahory, Nicole Molin, Yoram Kluger
    journal of Cancer Therapeutics and Research.2013; 2(1): 6.     CrossRef
  • Assessing the body image: relevance, application and instruments for oncological settings
    Maria Antonietta Annunziata, Lorena Giovannini, Barbara Muzzatti
    Supportive Care in Cancer.2012; 20(5): 901.     CrossRef
  • Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review
    Alyson L. Mahar, Natalie G. Coburn, Paul J. Karanicolas, Raymond Viola, Lucy K. Helyer
    Gastric Cancer.2012; 15(S1): 138.     CrossRef
  • Human hybrid endoscopic and laparoscopic management of mass lesions of the foregut (with video)
    Field F. Willingham, Sagar S. Garud, S. Scott Davis, Melinda M. Lewis, Shishir K. Maithel, David A. Kooby
    Gastrointestinal Endoscopy.2012; 75(4): 905.     CrossRef
  • Postoperative Quality of Life: Development and Validation of the “Dysfunction after Upper Gastrointestinal Surgery” Scoring System
    Misuzu Nakamura, Yoshinori Hosoya, Koji Umeshita, Masahiko Yano, Yuichiro Doki, Isao Miyashiro, Hideo Dannoue, Masaki Mori, Kentaro Kishi, Alan T. Lefor
    Journal of the American College of Surgeons.2011; 213(4): 508.     CrossRef
  • 10,878 View
  • 76 Download
  • 30 Crossref
Close layer
Clinicopathological and Immunohistochemical Features of Gastointestinal Stromal Tumors
Yu Na Kang, Hye Ra Jung, Ilseon Hwang
Cancer Res Treat. 2010;42(3):135-143.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.135
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to evaluate the clinicopathological features and immunohistochemical features of gastrointestinal stromal tumor (GIST), and specifically the expressions of platelet derived growth factor receptor A (PDGFRA), protein kinase C theta (PKC theta), discovered on GIST-1 (DOG-1), p16 and p27.

Materials and Methods

Total 118 patients who underwent surgical resection for GIST at our institution between Jan 1997 and Dec 2007 were retrospectively studied. Immunohistochemical staining for c-kit, PDGFRA, PKC-theta, DOG-1, p16 and p27 was performed on a tissue microarray of the 118 GIST. The clinicopathologic parameters, the disease-free survival (DFS) and the overall survival rate were analyzed along with immunohistochemistry.

Results

The immunohistochemical stains for c-kit, CD34, PKC-theta, PDGFRA, DOG-1, p16 and p27 were positive in 89.8%, 72.0%, 56.8%, 94.9%, 90.7%, 69.5% and 44.1% of the tumor samples, respectively. The immunohistochemical expression of c-kit was strongly correlated with PKC-theta (p=0.000), DOG-1 (p=0.000) and CD34 (p=0.002). The DFS rate was significantly decreased for the patients with peritoneal GIST, high risk GIST, ≥10 cm-sized GIST, ≥10 mitoses/50 high power fields (HPFs) and p16 positivity (p=0.001, p=0.004, p=0.001, p=0.003 and p=0.028). GISTs ≥10 cm, epithelioid tumor cell type, and c-kit, and DOG-1 negativity were significantly associated with shorter period of overall survival (p=0.048, p=0.006, p=0.000 and p=0.000).

Conclusion

The expression of p16 and no expression of c-kit and DOG-1 in GISTs, as well as peritoneal tumor site, high risk group, large tumor size, epithelioid tumor cell type and numerous mitoses, may be potentially prognostic factors for predicting worse outcome for patients who suffer from GIST.

Citations

Citations to this article as recorded by  
  • Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies
    Yang Yu, Mengdie Yu, Lijie Luo, Zijing Zhang, Haiping Zeng, Yan Chen, Zeyu Lin, Mengnan Chen, Wei Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor
    Pan Ran, Tao Tan, Hui Zhou, Jinjin Li, Hao Yang, Juan Li, Jun Zhang
    Journal of Personalized Medicine.2023; 13(3): 498.     CrossRef
  • Anti-KIT DNA aptamer-conjugated porous silicon nanoparticles for the targeted detection of gastrointestinal stromal tumors
    Sanahan Vijayakumar, Seyedmehdi H. Nasr, Jacob E. Davis, Edward Wang, Jonathan M. Zuidema, Yi-Sheng Lu, Yu-Hwa Lo, Jason K. Sicklick, Michael J. Sailor, Partha Ray
    Nanoscale.2022; 14(47): 17700.     CrossRef
  • Synovial sarcoma of the stomach: a case report and a systematic review of literature
    Yuko Kinowaki, Shiho Abe, Shinya Abe, Shohei Tomii, Akane Yukimori, Takumi Akashi, Masanori Tokunaga, Masanobu Kitagawa
    Clinical Journal of Gastroenterology.2021; 14(4): 1020.     CrossRef
  • DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples
    Kristina Jansen, Nagina Farahi, Franziska Büscheck, Maximilian Lennartz, Andreas M. Luebke, Eike Burandt, Anne Menz, Martina Kluth, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Sören Weidemann, Christoph Fraune, Katharina Möller, Patrick Lebok, Guid
    Pathology - Research and Practice.2021; 228: 153663.     CrossRef
  • GASTROINTESTINAL STROMAL TUMORS: A CLINICOPATHOLOGIC AND RISK STRATIFICATION STUDY OF 109 CASES IN SULAYMANIYAH CITY-KURDISTAN REGION OF IRAQ
    Barham Salih
    JOURNAL OF SULAIMANI MEDICAL COLLEGE.2021; 11(1): 45.     CrossRef
  • Gastrointestinal stromal tumor of the excluded stomach after Roux-en-Y gastric bypass: A case report and literature review
    Wagner A. Nascimento, Carlos Eduardo S. Macedo, Fernando Santa-Cruz, Henrique G.B. Coelho, Daniel T. Camelo Soares, Álvaro A.B. Ferraz
    International Journal of Surgery Case Reports.2020; 74: 196.     CrossRef
  • Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis
    Chayanit Jumniensuk, Mongkon Charoenpitakchai
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients
    David S. Moura, Rafael Ramos, Antonio Fernandez-Serra, Teresa Serrano, Julia Cruz, Ramiro Alvarez-Alegret, Rosa Ortiz-Duran, Luis Vicioso, Maria Luisa Gomez-Dorronsoro, Xavier Garcia del Muro, Javier Martinez-Trufero, Jordi Rubio-Casadevall, Isabel Sevill
    Oncotarget.2018; 9(25): 17576.     CrossRef
  • Review of gastrointestinal stromal tumors and contribution of dog1 immunohistochemical marker in diagnostics: A single tertiary centerb experience
    Andrej Belančić, Luka Vranić, Ivan Vuksan, Dora Fučkar Čupić, Dražen Kovač
    Medicina fluminensis.2017; 53(1): 78.     CrossRef
  • PKCθ utility in diagnosing c-KIT/DOG-1 double negative gastrointestinal stromal tumors
    Attila Kövecsi, Ioan Jung, Zoltan Szentirmay, Tivadar Bara, Tivadar Bara, Daniel Popa, Simona Gurzu
    Oncotarget.2017; 8(34): 55950.     CrossRef
  • Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
    Francesca Maria Rizzo, Raffaele Palmirotta, Andrea Marzullo, Nicoletta Resta, Mauro Cives, Marco Tucci, Franco Silvestris
    BMC Cancer.2016;[Epub]     CrossRef
  • Compound gastroenteropancreatic neuroendocrine and gastrointestinal stromal tumors in the stomach: A case report
    YU ZHOU, PING CHEN, LIANG ZHONG
    Oncology Letters.2015; 10(5): 2996.     CrossRef
  • An intra-abdominal desmoid tumor difficult to distinguish from a gastrointestinal stromal tumor: report of two cases
    Norihito Ogawa, Hideaki Iseki, Hidefumi Tsunozaki, Mikiko Hayashi, Hironobu Baba, Takatoshi Matsuyama, Hiroyuki Uetake, Kenichi Sugihara
    Surgery Today.2014; 44(11): 2174.     CrossRef
  • Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): A retrospective review of 114 patients from the French Sarcoma Group (FSG)
    F. Duffaud, P. Meeus, J.B. Bachet, P. Cassier, T.K. Huynh, E. Boucher, O. Bouché, V. Moutardier, A. le Cesne, B. Landi, F. Marchal, J.O. Bay, F. Bertucci, J.P. Spano, E. Stoeckle, O. Collard, L. Chaigneau, N. Isambert, V. Lebrun-Ly, J. Mancini, J.Y. Blay,
    European Journal of Surgical Oncology (EJSO).2014; 40(10): 1369.     CrossRef
  • Significance of surgery for prognosis of gist in cohort from transitional healthcare settings
    Mario Zovak, Marko Boban, Ljubica Boban, Slaven Cicek, Zrinko Madzar, Borislav Belev, Davor Tomas
    International Journal of Surgery.2014; 12(11): 1167.     CrossRef
  • Endoscopic full-thickness resection for gastric submucosal tumors arising from the muscularis propria layer
    Liu-Ye Huang
    World Journal of Gastroenterology.2014; 20(38): 13981.     CrossRef
  • Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
    Jason K. Sicklick, Nicole E. Lopez
    Journal of Gastrointestinal Surgery.2013; 17(11): 1997.     CrossRef
  • Retrospective study of endoscopic submucosal tunnel dissection (ESTD) for surgical resection of esophageal leiomyoma
    Lei Wang, Wei Ren, Zhimei Zhang, Jing Yu, Yihui Li, Yuankun Song
    Surgical Endoscopy.2013; 27(11): 4259.     CrossRef
  • Contribution of DOG1 expression to the diagnosis of gastrointestinal stromal tumors
    Tuba Kara, Ebru Serinsoz, Rabia Bozdogan Arpaci, Ozlem Gubur, Gulhan Orekici, Alper Ata, Tahsin Colak, Ali Arican
    Pathology - Research and Practice.2013; 209(7): 413.     CrossRef
  • Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours
    Chao Wang, Mei-Shan Jin, Ya-Bin Zou, Jing-Na Gao, Xiao-Bo Li, Fang Peng, Hai-Ying Wang, Zhen-Dong Wu, Yin-Ping Wang, Xiu-Mei Duan
    Scandinavian Journal of Gastroenterology.2013; 48(9): 1055.     CrossRef
  • Endoscopic full-thickness resection of gastric stromal tumor arising from the muscularis propria
    Bo ZHANG, Liu-ye HUANG, Cheng-rong WU, Jun CUI, Li-xin JIANG, Hai-tao ZHENG
    Chinese Medical Journal.2013; 126(13): 2435.     CrossRef
  • Deciding Laparoscopic Approaches for Wedge Resection in Gastric Submucosal Tumors: A Suggestive Flow Chart Using Three Major Determinants
    Chung-Ho Lee, Myung-Han Hyun, Ye-Ji Kwon, Sung-Il Cho, Sung-Soo Park
    Journal of the American College of Surgeons.2012; 215(6): 831.     CrossRef
  • Expression of DOG1, CD117 and PDGFRA in Gastrointestinal Stromal Tumors and Correlations with Clinicopathology
    Xiu-Wei Sun, Zhan-Jun Feng, Peng Huang, Wang Hao, Xing-Ling Sui
    Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1389.     CrossRef
  • Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report
    Daigo Yamamoto, Yoshinori Hamada, Yu Tsubota, Katsuhiro Kawakami, Chizuko Yamamoto, Mitsuo Yamamoto
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • A Rare Case of Gastrointestinal Stromal Tumour in Pregnancy Presenting with Upper Gastrointestinal Bleeding
    U. Parampalli, C. Crossland, J. Longley, I. Morrison, M. Sayegh
    Journal of Gastrointestinal Cancer.2012; 43(S1): 80.     CrossRef
  • Hemoperitôneo secundário a GIST gástrico c-KIT negativo e anticorpo anti-DOG1 positivo
    Marina Gabrielle Epstein, Aline Fioravanti Pasquetti, Sara Venoso Costa, Murillo de Lima Favaro, Orlando Contrucci Filho, Marcelo Augusto Fontenelle Ribeiro Junior
    Einstein (São Paulo).2012; 10(3): 377.     CrossRef
  • Exon 11 mutations, Ki67, and p16INK4A as predictors of prognosis in patients with GIST
    Marcelle R. Cerski, Fernanda Pereira, Ursula S. Matte, Francine H. Oliveira, Felipe L. Crusius, Luiz E. Waengertner, Alessandro Osvaldt, Fernando Fornari, Luise Meurer
    Pathology - Research and Practice.2011; 207(11): 701.     CrossRef
  • 13,639 View
  • 86 Download
  • 28 Crossref
Close layer
Prognostic Role of Rb, p16, Cyclin D1 Proteins in Soft Tissue Sarcomas
Byoung Yong Shim, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang
Cancer Res Treat. 2010;42(3):144-150.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.144
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.

Materials and Methods

We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.

Results

The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).

Conclusion

The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Citations

Citations to this article as recorded by  
  • Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors
    Mala Sagar, Rita Yadav, Pankaj Deval, Madhu Kumar, Malti K Maurya, Sumaira Qayoom
    Cureus.2023;[Epub]     CrossRef
  • Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas
    Jaffar Khan, Liang Cheng, Michael G. House, Shunhua Guo
    Current Oncology.2021; 28(6): 5295.     CrossRef
  • Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
    Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
    Laboratory Investigation.2019; 99(9): 1309.     CrossRef
  • Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis
    Gang Lin, Yue Lou
    Indian Journal of Cancer.2017; 54(3): 580.     CrossRef
  • GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
    Toshiaki Haraguchi, Hiroaki Miyoshi, Koji Hiraoka, Shintaro Yokoyama, Yukinao Ishibashi, Toshihiro Hashiguchi, Koutaro Matsuda, Tetsuya Hamada, Takahiro Okawa, Naoto Shiba, Koichi Ohshima, Ichiro Aoki
    PLOS ONE.2016; 11(6): e0156524.     CrossRef
  • Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
    Elisabetta Pennacchioli, Giulio Tosti, Massimo Barberis, Tommaso M. De Pas, Francesco Verrecchia, Claudia Menicanti, Alessandro Testori, Giovanni Mazzarol
    Clinical & Experimental Metastasis.2012; 29(7): 757.     CrossRef
  • 10,041 View
  • 65 Download
  • 6 Crossref
Close layer
Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications
Hyeong-Gon Moon, Sang-Ho Jeong, Young-Tae Ju, Chi-Young Jeong, Jong Sil Lee, Young-Joon Lee, Soon-Chan Hong, Sang-Kyung Choi, Woo-Song Ha, Soon-Tae Park, Eun-Jung Jung
Cancer Res Treat. 2010;42(3):151-156.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.151
AbstractAbstract PDFPubReaderePub
Purpose

Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial.

Materials and Methods

We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches.

Results

By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15).

Conclusion

Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.

Citations

Citations to this article as recorded by  
  • Differential functions of RhoGDIβ in malignant transformation and progression of urothelial cell following N-butyl-N-(4-hydmoxybutyl) nitrosamine exposure
    Xiaohui Hua, Ronghao Zou, Xiaoyue Bai, Yuyao Yang, Juan Lu, Chuanshu Huang
    BMC Biology.2023;[Epub]     CrossRef
  • Systematic investigation of biomarker-like role of ARHGDIB in breast cancer
    Xiaonan Wang, Xiaomin Bi, Xing Huang, Bijun Wang, Qianying Guo, Zhengsheng Wu
    Cancer Biomarkers.2020; 28(1): 101.     CrossRef
  • Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer
    Stefan Steurer, Benjamin Hager, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Sarah Minner, Till S. Clauditz, Claudia Hube-Magg, Andreas M. Luebke, Ronald Simon, Jakob R. Izbicki, Eike Burandt, Guido Sauter, Christoph Fraune, Sören Weid
    Aging.2019; 11(18): 7859.     CrossRef
  • Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation
    Ming-Chun Lai, Qian-Qian Zhu, Kwabena-Gyabaah Owusu-Ansah, Yang-Bo Zhu, Zhe Yang, Hai-Yang Xie, Lin Zhou, Li-Ming Wu, Shu-Sen Zheng
    Oncology Letters.2017; 14(2): 1395.     CrossRef
  • RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway
    Huiyan Niu, Baogang Wu, Yang Peng, Hongfang Jiang, Yi Zhang, Jiahe Wang, Yifei Zhang, Ping He
    Tumor Biology.2015; 36(1): 409.     CrossRef
  • Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors
    Jonathan Hensel, Jason E. Duex, Charles Owens, Garrett M. Dancik, Michael G. Edwards, Henry F. Frierson, Dan Theodorescu
    Molecular Cancer Research.2015; 13(9): 1306.     CrossRef
  • Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9
    Marcos A. Muñiz Lino, Yadira Palacios-Rodríguez, Sergio Rodríguez-Cuevas, Verónica Bautista-Piña, Laurence A. Marchat, Erika Ruíz-García, Horacio Astudillo-de la Vega, Ana E. González-Santiago, Ali Flores-Pérez, José Díaz-Chávez, Ángeles Carlos-Reyes, Eli
    Journal of Proteomics.2014; 111: 198.     CrossRef
  • Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway
    Weiming Duan, Yaxiang Xu, YuJin Dong, Lili Cao, Jian Tong, Xinwen Zhou
    Journal of Radiation Research.2013; 54(4): 611.     CrossRef
  • Expression of a tumor-associated gene, LASS2, in the human bladder carcinoma cell lines BIU-87, T24, EJ and EJ-M3
    QINGHUA ZHAO, HAIFENG WANG, MINGYING YANG, DELIN YANG, YIGANG ZUO, JIANSONG WANG
    Experimental and Therapeutic Medicine.2013; 5(3): 942.     CrossRef
  • RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration
    Neveen Said, Marta Sanchez-Carbayo, Steven C. Smith, Dan Theodorescu
    Journal of Clinical Investigation.2012; 122(4): 1503.     CrossRef
  • Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma
    Xianzheng Li, Jianmei Wang, Xiaojing Zhang, Yuanfeng Zeng, Li Liang, Yanqing Ding
    Annals of Surgical Oncology.2012; 19(1): 145.     CrossRef
  • Expression and prognostic significance of a new tumor metastasis suppressor gene LASS2 in human bladder carcinoma
    Haifeng Wang, Jiansong Wang, Yigang Zuo, Mingxia Ding, Ruping Yan, Delin Yang, Changxin Ke
    Medical Oncology.2012; 29(3): 1921.     CrossRef
  • The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder
    T Qayyum, G Fyffe, M Duncan, P A McArdle, M Hilmy, C Orange, G Halbert, M Seywright, P G Horgan, M A Underwood, J Edwards
    British Journal of Cancer.2012; 106(6): 1187.     CrossRef
  • The faces and friends of RhoGDI2
    Erin M. Griner, Dan Theodorescu
    Cancer and Metastasis Reviews.2012; 31(3-4): 519.     CrossRef
  • Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade
    MIGUEL A. FONSECA-SÁNCHEZ, SERGIO RODRÍGUEZ CUEVAS, GUILLERMO MENDOZA-HERNÁNDEZ, VERONICA BAUTISTA-PIÑA, ELENA ARECHAGA OCAMPO, ALFREDO HIDALGO MIRANDA, VALERIA QUINTANAR JURADO, LAURENCE A. MARCHAT, ELIZBETH ÁLVAREZ-SÁNCHEZ, CARLOS PÉREZ PLASENCIA, CÉSAR
    International Journal of Oncology.2012; 41(2): 670.     CrossRef
  • Reactive Center Loop Moiety Is Essential for the Maspin Activity on Cellular Invasion and Ubiquitin‐Proteasome Level
    Chakkrit Khanaree, Kongthawat Chairatvit, Sittiruk Roytrakul, Ariyaphong Wongnoppavich
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2012; 20(9): 427.     CrossRef
  • NFIB is a potential target for estrogen receptor‐negative breast cancers
    Hyeong-Gon Moon, Ki-Tae Hwang, Jeong-Ah Kim, Hee Sung Kim, Min-Joo Lee, Eun-Mi Jung, Eunyoung Ko, Wonshik Han, Dong-Young Noh
    Molecular Oncology.2011; 5(6): 538.     CrossRef
  • 11,345 View
  • 73 Download
  • 17 Crossref
Close layer
Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis
In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee
Cancer Res Treat. 2010;42(3):157-162.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.157
AbstractAbstract PDFPubReaderePub
Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by  
  • Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
    Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
    European Urology Open Science.2024; 69: 112.     CrossRef
  • Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
    Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
    Head and Neck Pathology.2024;[Epub]     CrossRef
  • Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
    Cancers.2021; 14(1): 51.     CrossRef
  • miR-205: A Potential Biomedicine for Cancer Therapy
    Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
    Cells.2020; 9(9): 1957.     CrossRef
  • Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
    Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
    Oral Diseases.2019; 25(4): 1158.     CrossRef
  • Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
    Philipp Wolf
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
    Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
    The Aging Male.2018; 21(3): 211.     CrossRef
  • Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
    Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
    Medicine.2018; 97(49): e13537.     CrossRef
  • Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
    R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
    Revista Mexicana de Urología.2016; 76(5): 288.     CrossRef
  • Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
    AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
    International Journal of Oncology.2014; 44(1): 195.     CrossRef
  • MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
    BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
    International Journal of Oncology.2013; 43(1): 307.     CrossRef
  • 9,075 View
  • 61 Download
  • 12 Crossref
Close layer
Influence of Reduced Folate Carrier and Dihydrofolate Reductase Genes on Methotrexate-Induced Cytotoxicity
Seong-Ae Yoon, Jung Ran Choi, Jeong-Oh Kim, Jung-Young Shin, XiangHua Zhang, Jin-Hyoung Kang
Cancer Res Treat. 2010;42(3):163-171.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.163
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study is to investigate the effect of genetic variations and the expression of the reduced folate carrier (RFC) and dihydrofolate reductase (DHFR) on the drug sensitivity to methotrexate (MTX) in different cancer cell lines.

Materials and Methods

We examined the six human cancer cell lines (MCF-7, AGS, A549, NCI-H23, HCT-116 and Saos-2). The cytotoxicity of MTX was measured by sulforhodamine B (SRB) assay. The expressions of the DHFR and RFC were evaluated by real-time PCR and western blotting. Four single nucleotide polymorphisms (SNPs) of the DHFR and two SNPs of the RFC were genotyped.

Results

The IC50s of MTX was in an extensively broad range from 6.05±0.81 nM to>1,000 nM in the cell lines. The Saos-2 (>1,000 nM) and MCF-7 (114.31±5.34 nM) cells were most resistant to MTX; in contrast, the AGS and HCT-116 cells were highly sensitive to MTX with an IC50 of 6.05±0.81 nM and 13.56±3.76 nM, respectively. A reciprocal change of the RFC and DHFR mRNA expression was found between the MTX-sensitive AGS and MTX-resistant Saos-2 cells. There was no significant difference in the expression levels of RFC protein in both the AGS and Saos-2 cells, whereas DHFR protein was more increased in the MTX-resistant Saos-2 cells treated with MTX. The genotype of the MTX-sensitive AGS cells were mutant variants of the DHFR; in contrast, the Saos-2 cells had the wild-type of the DHFR.

Conclusion

In conclusion, this study showed that inverse change of the RFC and DHFR mRNA and protein expression was associated with RFC and DHFR polymorphisms and it is postulated that this phenomenon might play an important role in sensitivity of certain cancers to MTX.

Citations

Citations to this article as recorded by  
  • Non-uniformity in in vitro drug-induced cytotoxicity as evidenced by differences in IC50 values – implications and way forward
    T. Arokia Femina, V. Barghavi, K. Archana, N.G. Swethaa, Ravi Maddaly
    Journal of Pharmacological and Toxicological Methods.2023; 119: 107238.     CrossRef
  • Cluster of resistance-inducing genes in MCF-7 cells by estrogen, insulin, methotrexate and tamoxifen extracted via NMF
    Angelina Boccarelli, Nicoletta Del Buono, Flavia Esposito
    Pathology - Research and Practice.2023; 242: 154347.     CrossRef
  • Methotrexate-Induced Subacute Combined Degeneration in Acute Lymphoblastic Leukemia with CNS Relapse May Be Reversible
    David Bared Dukenik, Deborah Soong, Wenhui Li, Ellen Madarang, Justin Watts, Justin Taylor
    Hemato.2023; 4(4): 311.     CrossRef
  • Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study
    Han Cen, Qin-Wen Wen, Han-Qing Zhang, Hang Yu, Zhen Zeng, Ting Jin, Ting-Hui Wang, Wen Qin, Hua Huang, Xiu-Di Wu
    Pharmacogenomics and Personalized Medicine.2022; Volume 15: 327.     CrossRef
  • Development and Optimization of Methotrexate Encapsulated Polymeric Nanocarrier by Ionic Gelation Method and its Evaluations
    Rinki Verma, Manoj Kumar
    ChemistrySelect.2022;[Epub]     CrossRef
  • Preparation, characterization and in vitro antitumor activity evaluation of hyaluronic acid-alendronate-methotrexate nanoparticles
    Chunxia Gao, Mengmeng Wang, Peizhi Zhu, Caifeng Yan
    International Journal of Biological Macromolecules.2021; 166: 71.     CrossRef
  • Auger electron therapy of glioblastoma using [125I]5-iodo-2′-deoxyuridine and concomitant chemotherapy – Evaluation of a potential treatment strategy
    Karina Lindbøg Madsen, Anne Sofie Nautrup Therkelsen, Niels Langkjær, Birgitte Brinkmann Olsen, Helge Thisgaard
    Nuclear Medicine and Biology.2021; 96-97: 35.     CrossRef
  • Thermosensitive hydrogel for in situ-controlled methotrexate delivery
    Teresa Darlen Carrillo-Castillo, Antonia Luna-Velasco, Erasto Armando Zaragoza-Contreras, Javier Servando Castro-Carmona
    e-Polymers.2021; 21(1): 910.     CrossRef
  • Process optimization by response surface methodology for preparation and evaluation of methotrexate loaded chitosan nanoparticles
    N. Raghavendra Naveen, Mallesh Kurakula, Buduru Gowthami
    Materials Today: Proceedings.2020; 33: 2716.     CrossRef
  • The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
    Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor
    Oncotarget.2020; 11(18): 1576.     CrossRef
  • Omega-3 offers better hypothalamus protection by decreasing POMC expression and elevating ghrelin hormone: a prospective trial to overcome methotrexate-induced anorexia
    Heba Mostafa, Lamia Barakat, Walied S. Abdo, Rania M. Khalil
    Endocrine.2020; 69(2): 358.     CrossRef
  • Cellular Analysis and Chemotherapeutic Potential of a Bi-Functionalized Halloysite Nanotube
    Yangyang Luo, Ahmed Humayun, Teresa A. Murray, Benjamin S. Kemp, Antwine McFarland, Xuan Liu, David K. Mills
    Pharmaceutics.2020; 12(10): 962.     CrossRef
  • Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives
    Samar El-Kalyoubi, Fatimah Agili
    Molecules.2020; 25(21): 5205.     CrossRef
  • Recent Advances and Developments of in vitro Evaluation of Heterocyclic Moieties on Cancer Cell Lines
    Runjhun Tandon, Iqubal Singh, Vijay Luxami, Nitin Tandon, Kamaldeep Paul
    The Chemical Record.2019; 19(2-3): 362.     CrossRef
  • Methotrexate induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system
    Yanfei Shao, Biqin Tan, Jing Shi, Qian Zhou
    Toxicology Letters.2019; 301: 146.     CrossRef
  • PEGAylated graphene oxide/superparamagnetic nanocomposite as a high-efficiency loading nanocarrier for controlled delivery of methotrexate
    Zahra Abdollahi, Asghar Taheri-Kafrani, Seyed Amir Bahrani, Abolghasem Abbasi Kajani
    Journal of Biotechnology.2019; 298: 88.     CrossRef
  • Lipidic Liquid Crystalline Cubic Phases and Magnetocubosomes as Methotrexate Carriers
    Monika Mierzwa, Adrianna Cytryniak, Paweł Krysiński, Renata Bilewicz
    Nanomaterials.2019; 9(4): 636.     CrossRef
  • Actively Targeted and Redox Responsive Delivery of Anticancer Drug by Chitosan Nanoparticles
    Elisabetta Mazzotta, Selene De Benedittis, Antonio Qualtieri, Rita Muzzalupo
    Pharmaceutics.2019; 12(1): 26.     CrossRef
  • Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate)
    Jiraphong Suksiriworapong, Vincenzo Taresco, Delyan P. Ivanov, Ioanna D. Styliari, Krisada Sakchaisri, Varaporn Buraphacheep Junyaprasert, Martin C. Garnett
    Colloids and Surfaces B: Biointerfaces.2018; 167: 115.     CrossRef
  • Methotrexate-Coated Complexes of Plasmid DNA and Polyethylenimine for Gene Delivery
    Yukinobu Kodama, Ryo Noda, Kayoko Sato, Hitomi Harasawa, Tomoaki Kurosaki, Hiroo Nakagawa, Tadahiro Nakamura, Takashi Kitahara, Takahiro Muro, Hitoshi Sasaki
    Biological and Pharmaceutical Bulletin.2018; 41(10): 1537.     CrossRef
  • Synthesis and in vitro evaluation of pH-sensitive magnetic nanocomposites as methotrexate delivery system for targeted cancer therapy
    Juan Wu, Aipeng Deng, Wei Jiang, Renbing Tian, Yewen Shen
    Materials Science and Engineering: C.2017; 71: 132.     CrossRef
  • Spatial controlled multistage nanocarriers through hybridization of dendrimers and gelatin nanoparticles for deep penetration and therapy into tumor tissue
    Yuchao Fan, Shengxiao Yuan, MengMeng Huo, Arka Sen Chaudhuri, Meihui Zhao, Zhenghong Wu, Xiaole Qi
    Nanomedicine: Nanotechnology, Biology and Medicine.2017; 13(4): 1399.     CrossRef
  • WITHDRAWN: A fractional factorial design to study the effect of process variables on preparation of methotrexate loaded chitosan nanoparticles
    N Raghavendra Naveen, T S Nagaraja, Chakka Gopinath, S V Gopala Krishna, Buduru Gowthami, S Prasanthi, K Mallikarjuna Rao, T Reddi Soundarya, P Jyothsna, G Poojitha
    OpenNano.2017;[Epub]     CrossRef
  • Folate Metabolism Regulates Oligodendrocyte Survival and Differentiation by Modulating AMPKα Activity
    Qinjie Weng, Jiajia Wang, Jiaying Wang, Biqin Tan, Jing Wang, Haibo Wang, Tao Zheng, Q. Richard Lu, Bo Yang, Qiaojun He
    Scientific Reports.2017;[Epub]     CrossRef
  • Theranostic carbon dots ‘clathrate-like’ nanostructures for targeted photo-chemotherapy and bioimaging of cancer
    Sunil Pandey, Ganga Raju Gedda, Mukeshchand Thakur, Mukesh Lavkush Bhaisare, Abou Talib, M. Shahnawaz Khan, Shou-Mei Wu, Hui-Fen Wu
    Journal of Industrial and Engineering Chemistry.2017; 56: 62.     CrossRef
  • A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer
    Masataka Nakano, Tatsuki Fukami, Saki Gotoh, Miki Nakajima
    Journal of Biological Chemistry.2017; 292(12): 4873.     CrossRef
  • The impact of methotrexate on lung inflammatory and apoptotic pathway biomarkers—The role of gallic acid
    Mustafa Saygin, Onder Ozturk, Ozlem Ozmen, Ilter Ilhan, Taner Gonca, Nurhan Gumral, Hikmet Orhan, Rahime Aslankoc
    Biomedicine & Pharmacotherapy.2016; 84: 1689.     CrossRef
  • Interaction of methotrexate, an anticancer agent, with copper(II) ions: coordination pattern, DNA-cleaving properties and cytotoxic studies
    Justyna Nagaj, Paulina Kołkowska, Aleksandra Bykowska, Urszula K. Komarnicka, Agnieszka Kyzioł, Małgorzata Jeżowska-Bojczuk
    Medicinal Chemistry Research.2015; 24(1): 115.     CrossRef
  • Boronate Cross‐linked ATP‐ and pH‐Responsive Nanogels for Intracellular Delivery of Anticancer Drugs
    Xuejiao Zhang, Katharina Achazi, Rainer Haag
    Advanced Healthcare Materials.2015; 4(4): 585.     CrossRef
  • Construction of pH-sensitive lysozyme/pectin nanogel for tumor methotrexate delivery
    Liufeng Lin, Wei Xu, Hongshan Liang, Lei He, Shilin Liu, Yan Li, Bin Li, Yijie Chen
    Colloids and Surfaces B: Biointerfaces.2015; 126: 459.     CrossRef
  • PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal models
    Dipti Kakkar, Shweta Dumoga, Rohit Kumar, Krishna Chuttani, Anil Kumar Mishra
    MedChemComm.2015; 6(8): 1452.     CrossRef
  • DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: The same outcome of treatment with different doses in sensitive cell lines
    Jakub Neradil, Gabriela Pavlasova, Martin Sramek, Michal Kyr, Renata Veselska, Jaroslav Sterba
    Oncology Reports.2015;[Epub]     CrossRef
  • Spontaneously-forming spheroids as anin vitrocancer cell model for anticancer drug screening
    Maria A. Theodoraki, Celso O. Rezende, Oraphin Chantarasriwong, Adriana D. Corben, Emmanuel A. Theodorakis, Mary L. Alpaugh
    Oncotarget.2015; 6(25): 21255.     CrossRef
  • Injectable poly(organophosphazene) hydrogel system for effective paclitaxel and doxorubicin combination therapy
    Jung-Kyo Cho, Hyo-Jeong Kuh, Soo-Chang Song
    Journal of Drug Targeting.2014; 22(8): 761.     CrossRef
  • Adipose-derived stem cells retain their regenerative potential after methotrexate treatment
    Olivia S. Beane, Vera C. Fonseca, Eric M. Darling
    Experimental Cell Research.2014; 327(2): 222.     CrossRef
  • Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis, Characterization, and in Vitro and in Vivo Antitumoral Activity
    Juan Chen, Liuqing Huang, Huixian Lai, Chenghao Lu, Ming Fang, Qiqing Zhang, Xuetao Luo
    Molecular Pharmaceutics.2014; 11(7): 2213.     CrossRef
  • pH/redox responsive core cross-linked nanoparticles from thiolated carboxymethyl chitosan for in vitro release study of methotrexate
    Cheng Gao, Ting Liu, Yinghua Dang, Zhiyan Yu, Wei Wang, Jingjing Guo, Xueqiong Zhang, Guanghua He, Hua Zheng, Yihua Yin, Xiangqi Kong
    Carbohydrate Polymers.2014; 111: 964.     CrossRef
  • Electrochemically controlled release of anticancer drug methotrexate using nanostructured polypyrrole modified with cetylpyridinium: Release kinetics investigation
    Naader Alizadeh, Ehsan Shamaeli
    Electrochimica Acta.2014; 130: 488.     CrossRef
  • Mg–Al layered double hydroxide–methotrexate nanohybrid drug delivery system: Evaluation of efficacy
    Jui Chakraborty, Susanta Roychowdhury, Somoshree Sengupta, Swapankumar Ghosh
    Materials Science and Engineering: C.2013; 33(4): 2168.     CrossRef
  • Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma
    Fabian Mairinger, Claudia Vollbrecht, Iris Halbwedl, Martina Hatz, Elvira Stacher, Christian Gülly, Franz Quehenberger, Susann Stephan-Falkenau, Jens Kollmeier, Andreas Roth, Thomas Mairinger, Helmut Popper
    Journal of Thoracic Oncology.2013; 8(5): 644.     CrossRef
  • In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles
    Daniele Rubert Nogueira, Lorena Tavano, Montserrat Mitjans, Lourdes Pérez, M. Rosa Infante, M. Pilar Vinardell
    Biomaterials.2013; 34(11): 2758.     CrossRef
  • Injectable poly(organophosphazene)–camptothecin conjugate hydrogels: Synthesis, characterization, and antitumor activities
    Jung-Kyo Cho, ChangJu Chun, Hyo-Jeong Kuh, Soo-Chang Song
    European Journal of Pharmaceutics and Biopharmaceutics.2012; 81(3): 582.     CrossRef
  • Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
    M. Joerger, A. D. R. Huitema, G. Illerhaus, A. J. M. Ferreri
    Leukemia & Lymphoma.2012; 53(10): 1867.     CrossRef
  • Selective N-Alkylation of β-Alanine Facilitates the Synthesis of a Poly(amino acid)-Based Theranostic Nanoagent
    Santimukul Santra, J. Manuel Perez
    Biomacromolecules.2011; 12(11): 3917.     CrossRef
  • Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy
    Santimukul Santra, Charalambos Kaittanis, Oscar J. Santiesteban, J. Manuel Perez
    Journal of the American Chemical Society.2011; 133(41): 16680.     CrossRef
  • The reduced folate carrier-1 (RFC1 696T>C) polymorphism is associated with spontaneously aborted embryos in Koreans
    Young Joo Jeon, Yi Seul Choi, HyungChul Rah, Youngsok Choi, Tae Ki Yoon, Dong Hee Choi, Nam Keun Kim
    Genes & Genomics.2011; 33(3): 223.     CrossRef
  • 13,151 View
  • 152 Download
  • 46 Crossref
Close layer
Case Reports
A Case of Metachronous Metastasis to the Breast from Non-Small Cell Lung Carcinoma
Min Yong Yoon, Chang Seok Song, Mi Hae Seo, Min Jae Kim, Tae Yun Oh, Un Ha Jang, Hyon Joo Kwag, Hee Sung Kim, Si Young Lim, Seong Yong Lim, Seung Sae Lee
Cancer Res Treat. 2010;42(3):172-175.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.172
AbstractAbstract PDFPubReaderePub

Breast metastases from an extramammary primary tumor are very rare and the prognosis for such patients is generally poor. We report here on a case of a 42-year-old female with metastasis of non-small cell lung cancer to the breast, and she is now being followed up on an outpatient basis. In 2004, she presented with a solitary pulmonary nodule in the left lung, and this lesion had been noted to have gradually increased in size over time. The final pathological diagnosis was adenocarcinoma, and the diagnosis was made by performing percutaneous needle aspiration and lobectomy of the left upper lobe. Adjuvant chemotherapy and radiotherapy were given. Unfortunately, a nodule in the left breast was noted three years later, and metastatic non-small-cell lung cancer to the breast was diagnosed by excisional biopsy. Making the correct diagnosis to distinguish a primary breast carcinoma from a metastatic one is important, because the therapeutic plan and outcome for these two types of cancer are quite different.

Citations

Citations to this article as recorded by  
  • A Rare Case of Breast Metastasis from a Primary Lung Tumor: Case Report
    Raquel Diaz, Federica Murelli, Letizia Cuniolo, Chiara Cornacchia, Francesca Depaoli, Cecilia Margarino, Chiara Boccardo, Marco Gipponi, Simonetta Franchelli, Marianna Pesce, Barbara Massa, Silvia Bozzano, Valentina Barbero, Franco De Cian, Piero Fregatti
    Current Oncology.2024; 31(8): 4695.     CrossRef
  • Breast metastasis from primary lung adenocarcinoma in a young woman: A case report and literature review
    Diego Enrico, Silvia Saucedo, Inés Bravo
    World Journal of Clinical Oncology.2019; 10(7): 269.     CrossRef
  • ‘Inflammatory breast cancer’ due to metastatic adenocarcinoma of lung
    Jacob Ninan, Vinay Naik, Gemy Maria George
    BMJ Case Reports.2016; : bcr2016215857.     CrossRef
  • Metastasis of primary lung carcinoma to the breast: a systematic review of the literature
    Jennifer A. Mirrielees, Jaime H. Kapur, Linda M. Szalkucki, Josephine M. Harter, Lonie R. Salkowski, Roberta M. Strigel, Anne M. Traynor, Lee G. Wilke
    Journal of Surgical Research.2014; 188(2): 419.     CrossRef
  • Métastases mammaires de cancers d’origine extra-mammaire : état des lieux et difficultés diagnostiques
    A. Koch, A. Richter-Marot, M.P. Wissler, A. Baratte, C. Mathelin
    Gynécologie Obstétrique & Fertilité.2013; 41(11): 653.     CrossRef
  • Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence?
    Hsu-Ching Huang, Jen-Fan Hang, Mei-Han Wu, Teh-Ying Chou, Chao-Hua Chiu
    Journal of Thoracic Oncology.2013; 8(7): 974.     CrossRef
  • Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: Systematic review and analysis of reported cases
    Samer Salah, Tawee Tanvetyanon, Salah Abbasi
    Lung Cancer.2012; 75(1): 9.     CrossRef
  • 8,881 View
  • 65 Download
  • 7 Crossref
Close layer
Recurrent and Metastatic Trichilemmal Carcinoma of the Skin Over the Thigh: A Case Report
Hyon Seung Yi, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Seung-Yeon Ha, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2010;42(3):176-179.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.176
AbstractAbstract PDFPubReaderePub

Trichilemmal carcinoma (TC) is an uncommon cutaneous neoplasm that develops from the external root sheath of the hair follicle. It is considered to be a low-grade carcinoma with low metastatic potential. Local recurrence and metastasis are rare after surgical excision. We report here on a case of metastatic TC in the skin over the thigh, and this tumor was treated with cisplatin and cyclophosphamide combination chemotherapy.

Citations

Citations to this article as recorded by  
  • Trichilemmal carcinoma metastatic to parotid gland: First report of fine needle aspiration cytology features
    Priya Jayakumar, Aanchal Kakkar, Sudheer Arava, Supriya Mallick
    Diagnostic Cytopathology.2024;[Epub]     CrossRef
  • Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review
    Lei Liu, Tengfei Long, Nannan Wei, Hongyan Zhang, Chaoliang Tang, Jin Gao
    Immunotherapy.2024; 16(10): 659.     CrossRef
  • A Rare Case of Trichilemmal Carcinoma of the Scalp
    Raymart Macasaet, FNU Arty, Janelle du Toit, Sai Gaddameedi, Shazia M Shah
    Cureus.2024;[Epub]     CrossRef
  • Malignant pilar cyst in a young woman: Case report and literature review
    Ali Ibrahim Ali Hegy, Amina Ibrahim El-yakub, Yaser Taha Sidahmed
    International Journal of Case Reports and Images.2024; 15(1): 89.     CrossRef
  • A Rare Case Of Trichilemmal Carcinoma In A Sun-unexposed Area
    Alemwosen Alem, Alazar Aregawi, Teketel Geremew
    Journal of Global Surgery (ONE).2024;[Epub]     CrossRef
  • Systematic analysis and case series of the diagnosis and management of trichilemmal carcinoma
    Jiachen Sun, Lihua Zhang, Minglu Xiao, Shiyi Li, Runkai Chen, Ying Li, Yuguang Yang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • When to sweat: A history of chemotherapy in malignant sweat gland tumors. A unique case report and literature review
    J. Matthiesen, R. Chiu, T. T. Do, S. Bamdad, J. Lee, S. K. Peng
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Recurrent trichilemmal carcinoma of the periorbital region treated with IMRT radiotherapy: A case report and a review of literature
    Shan Gao, Qin Xu, Yanli Lan, Lang He
    Medicine.2023; 102(24): e34038.     CrossRef
  • Malignant proliferating trichilemmal tumor in abdominal wall: Report of a rare case at an uncommon site with literature review
    Mahdokht Azizi, Mazaher Ramezani
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Trichilemmal Carcinoma of the Scalp in a Young Female: A Case Report
    Qiuyu Jia, Yunyan Yuan, Dandan Mao, Guangdong Wen, Xue Chen
    Clinical, Cosmetic and Investigational Dermatology.2022; Volume 15: 139.     CrossRef
  • Current Treatment Options for Cutaneous Adnexal Malignancies
    Hiroyuki Goto
    Current Treatment Options in Oncology.2022; 23(5): 736.     CrossRef
  • Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
    Iga Płachta, Marcin Kleibert, Anna M. Czarnecka, Mateusz Spałek, Anna Szumera-Ciećkiewicz, Piotr Rutkowski
    International Journal of Molecular Sciences.2021; 22(9): 4759.     CrossRef
  • Huge Trichilemmal Carcinoma With Metastasis Presenting With Two Distinct Histological Morphologies: A Case Report
    Yao Xie, Lin Wang, Tingting Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Trichilemmal carcinoma in a patient with squamous cell skin cancer
    V. A. Smolyannikova, M. A. Nefedova
    Arkhiv patologii.2019; 81(1): 31.     CrossRef
  • Locally aggressive trichilemmal carcinoma
    Ana María Maya-Rico, Catalina Jaramillo-Pulgarín, Ángela Londoño-García, Bibiana Peña-Zúñiga
    Anais Brasileiros de Dermatologia.2018; 93(4): 579.     CrossRef
  • Cells to Surgery Quiz: April 2018
    Ali Rajabi-Estarabadi, Sofia Iglesia, Jacob W. Griggs, Pooja Gurnani, Samuel C. Smith, Cassandra IF. Collins, Keyvan Nouri
    Journal of Investigative Dermatology.2018; 138(4): e37.     CrossRef
  • Adnexal Carcinomas Treated With Mohs Micrographic Surgery: A Comprehensive Review
    Stanislav N. Tolkachjov
    Dermatologic Surgery.2017; 43(10): 1199.     CrossRef
  • Malignant hair follicle tumors of the periorbital region: A review of literature and suggestion of a management guideline
    Paul Ikgan Sia, Edwin Figueira, Alexandra Allende, Dinesh Selva
    Orbit.2016; 35(3): 144.     CrossRef
  • Metastatic trichilemmal carcinoma in a patient with breast cancer
    Chrysis Sofianos, Nkhensani Y Chauke, Alexandra Grubnik
    BMJ Case Reports.2016; : bcr2016217661.     CrossRef
  • A Case of Trichilemmal Carcinoma With Distant Metastases in a Kidney Transplantation Patient
    K. Hiramatsu, K. Sasaki, M. Matsuda, M. Hashimoto, T. Eguchi, S. Tomikawa, T. Fujii, G. Watanabe
    Transplantation Proceedings.2015; 47(1): 155.     CrossRef
  • Challenges in the diagnosis of cutaneous adnexal tumours
    Richard Danialan, Kudakwashe Mutyambizi, Phyu P Aung, Victor G Prieto, Doina Ivan
    Journal of Clinical Pathology.2015; 68(12): 992.     CrossRef
  • Survival study and clinicopathological evaluation of trichilemmal carcinoma
    SHI-MIN ZHUANG, GE-HUA ZHANG, WEN-KUAN CHEN, SHU-WEI CHEN, LI-PING WANG, HUAN LI, MING SONG
    Molecular and Clinical Oncology.2013; 1(3): 499.     CrossRef
  • Unusual Invasion of Trichilemmal Umors: Two Case Reports
    Mehtap Karamese, Ahmet Akatekin, Malik Abaci, Zekeriya Tosun, Mustafa Keskin
    Modern Plastic Surgery.2012; 02(03): 54.     CrossRef
  • 9,776 View
  • 71 Download
  • 23 Crossref
Close layer
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
Cancer Res Treat. 2010;42(3):180-184.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.180
AbstractAbstract PDFPubReaderePub

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.

Citations

Citations to this article as recorded by  
  • Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
    Elodie Klajer, Louis Garnier, Morgan Goujon, Friederike Schlurmann-Constans, Benoite Mery, Thierry Nguyen Tan Hon, Guillaume Mouillet, Fabien Calcagno, Antoine Thiery-Vuillemin
    Seminars in Oncology.2020; 47(2-3): 103.     CrossRef
  • Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
    Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini, Camillo Porta
    EMJ Nephrology.2016; : 66.     CrossRef
  • Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
    Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro
    Current Urology Reports.2015;[Epub]     CrossRef
  • Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of Experience
    Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk, Cezary Szczylik
    Future Oncology.2015; 11(16): 2267.     CrossRef
  • Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
    Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong-Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha
    European Journal of Cancer.2014; 50(4): 746.     CrossRef
  • Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
    Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
    Korean Journal of Urology.2014; 55(1): 74.     CrossRef
  • A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
    Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte, Pierre I. Karakiewicz
    Cancer Treatment Reviews.2013; 39(4): 388.     CrossRef
  • Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
    Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moscetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cin
    BJU International.2012; 110(5): 692.     CrossRef
  • 10,019 View
  • 67 Download
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP